Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.56 |
| ▸ | RAB9A | P51151 | 10/20 | 0.56 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652624 | 0.82 | NPC1 (0.61) | NPC1RAB9ANR0B1MEN1KMT2A | |
| SCHEMBL8510246 | 0.82 | NPC1 (0.51) | NPC1RAB9ANR0B1MEN1KMT2A | |
| SCHEMBL5629538 | 0.81 | RAB9A (0.65) | NPC1RAB9AKMT2AATML3MBTL1 | |
| SCHEMBL4272878 | 0.81 | MEN1 (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL31076256 | 0.81 | MEN1 (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL30421156 | 0.81 | RAB9A (0.65) | NPC1RAB9AKMT2AATML3MBTL1 | |
| SCHEMBL5631579 | 0.81 | NPC1 (0.55) | NPC1RAB9ANR0B1MEN1KMT2A | |
| SCHEMBL6361946 | 0.80 | RAB9A (0.58) | NPC1RAB9ANR0B1MEN1KMT2A | |
| SCHEMBL16303154 | 0.80 | NPC1 (0.52) | NPC1RAB9ANR0B1MEN1KMT2A | |
| SCHEMBL2601270 | 0.80 | NPC1 (0.52) | NPC1RAB9ANR0B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874130-A | Thiocyanate radical removing method for enhancing electron transfer and transfer | 中国科学院生态环境研究中心 | 2025-04-25 | — | — | CN | claimed |
| CN-119874130-A | Thiocyanate radical removing method for enhancing electron transfer and transfer | 中国科学院生态环境研究中心 | 2025-04-25 | — | — | CN | disclosed |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20220127267-A1 | THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-9593095-B2 | Methods for the treatment of bacterial infections | DUKE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140371194-A1 | METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | THE UNIVERSITY OF KANSAS | 2014-12-18 | — | — | US | disclosed |
| EP-0819000-B1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-7169927-B2 | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2007-01-30 | — | — | US | disclosed |
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| US-5962499-A | ACARICIDAL, ANTIPARASITIC, INSECTICIDAL AND ANTHELMINTIC AGENTS | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0356234-B1 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-5047411-A | Antiulcer Agents, H2-Receptor Antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0356234-A2 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | PYGL, PYGM, GYS1 | NPC1 935/4885RAB9A 558/4885NR0B1 440/4885 |
| US-20220127267-A1 | THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS | PDK2, PDK1, PDK3 | NPC1 4625/4885RAB9A 3825/4885NR0B1 738/4885 |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | NPC1 1575/4885RAB9A 398/4885NR0B1 1142/4885 |
| US-20050131016-A1 | Chemical compounds | PYGL, GYS1, CA9 | NPC1 642/4885RAB9A 560/4885NR0B1 276/4885 |
| US-20140371194-A1 | METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CRYAB, HSP90B1, SERPINB1 | NPC1 1325/4885RAB9A 2197/4885NR0B1 3652/4885 |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | NPC1 3175/4885RAB9A 3922/4885NR0B1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.